National Psoriasis Foundation awards more than $2 million for research 
MarketWatch (press release)
Twenty-six scientists have received a total of $2.06 million in grants from the National Psoriasis Foundation to study psoriasis--the most common autoimmune disease in the country, affecting as many as 7.5 million Americans--and psoriatic arthritis, ...

and more » 

National Psoriasis Foundation awards more than $2 million for research 
Sacramento Bee
These fellowships provide support of up to $40000 per year to new doctors training to do research in psoriasis and psoriatic arthritis. The fellowships are intended to increase the number of doctors studying psoriatic diseases.

and more » 

The Heartbreak of Psoriasis 
Patch.com
The title of this week's column used to be a "back in the day" catchy slogan for a remedy that was touted to "cure" psoriasis. It became a running joke amongst my friends and I, silly teenagers, but for anyone who suffers from this disorder, ...

 

Undervalued Picks From A Pro Investor 
Seeking Alpha
Remicade overall has received approval for several indications including Crohn's disease, ankylosing spondylitis, psoriasis, psoriatic arthritis, ulcerative colitis and rheumatoid arthritis. Remicade growth derives from strong demand in the rheumatoid ...

and more » 

GSK Researchers Use GWAS Data to Find Possible New Uses for Existing Therapies 
GenomeWeb
For example, denosumab, a monoclonal antibody marketed as Prolia by Amgen for osteoporosis and bone cancer, targets the TNFSF11 gene, which, in addition to its link to bone disease has also been associated with Crohn's disease by GWAS, the paper states ...

 

Novartis AG's CEO Discusses Q1 2012 Results - Earnings Call Transcript 
Seeking Alpha
So 2 new molecules approved in Pharma, Signifor for Cushing's disease and Jakavi for myelofibrosis. Also very nice Phase III clinical trials on QVA149. This is going to be an important drug for Novartis in COPD going forward.

and more »